Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.ijcard.2012.01.065
Title: Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years
Authors: Chan, M.Y. 
Sun, J.-L.
Newby, L.K.
Lokhnygina, Y.
White, H.D.
Moliterno, D.J.
Théroux, P.
Ohman, E.M.
Simoons, M.L.
Mahaffey, K.W.
Pieper, K.S.
Giugliano, R.P.
Armstrong, P.W.
Califf, R.M.
Van De Werf, F.
Harrington, R.A.
Keywords: Antithrombotic therapy
Non-ST-segment elevation acute coronary syndromes
Outcomes
Randomized clinical trials
Risk
Issue Date: 31-Jul-2013
Citation: Chan, M.Y., Sun, J.-L., Newby, L.K., Lokhnygina, Y., White, H.D., Moliterno, D.J., Théroux, P., Ohman, E.M., Simoons, M.L., Mahaffey, K.W., Pieper, K.S., Giugliano, R.P., Armstrong, P.W., Califf, R.M., Van De Werf, F., Harrington, R.A. (2013-07-31). Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years. International Journal of Cardiology 167 (2) : 548-554. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ijcard.2012.01.065
Abstract: Background: Data are limited on whether clinical trials have randomized higher-risk patients over time and how trends in risk profiles and evidence-based pharmacotherapies have influenced trial outcomes. We quantified changes in baseline risk, treatment, and outcomes of patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) randomized in 9 phase 3 clinical trials of antithrombotic therapy over 15 years. Methods: We studied 58,771 patients in GUSTO IIb, PURSUIT, PARAGON-A, PARAGON-B, PRISM, PRISM-PLUS, GUSTO IV-ACS, SYNERGY, and EARLY ACS. Patient-level data were mapped to 3 pre-specified 5-year randomization periods. Temporal trends in GRACE score-predicted mortality were compared with trends in observed mortality. Results: Over time, in-hospital and discharge use of thienopyridines (p = 0.001), statins (p < 0.0001), and angiotensin-converting enzyme inhibitors (p < 0.0001) increased, and hospital length-of-stay decreased (p = 0.024). Blood transfusion use increased (8.3% [1994-98], 10.7% [1999-2003], 13% [2004-08], p = 0.0002) despite stable rates of severe bleeding (0.9% [1994-98], 1.4% [1999-2003] and 1.1% [2004-08], p = 0.127) and coronary artery bypass grafting (12.4% [1994-98], 13.7% [1999-2003] 13.1% [2004-08], p = 0.880). Although predicted 6-month mortality increased (6.9% [1994-98], 9.0% [1999-2003], 7.9% [2004-08], p = 0.017), observed 6-month mortality decreased (6.7% [1994-98], 5.8% [1999-2003], 5.1% [2004-08], p = 0.025). Thirty-day myocardial infarction rates remained stable (9.2% [1994-98], 9.3% [1999-2003], 10% [2004-08], p = 0.539). Conclusions: Despite enrolling higher-risk patients into these NSTE ACS trials, with better treatment, observed mortality declined over the past 15 years. The appropriateness of increased blood transfusion despite unchanged bleeding rates deserves further study. © 2013 Elsevier Ireland Ltd. All rights reserved.
Source Title: International Journal of Cardiology
URI: http://scholarbank.nus.edu.sg/handle/10635/126874
ISSN: 01675273
DOI: 10.1016/j.ijcard.2012.01.065
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

7
checked on Sep 15, 2019

WEB OF SCIENCETM
Citations

7
checked on Sep 6, 2019

Page view(s)

28
checked on Sep 6, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.